ep ahead temper expect
handili exceed estim stronger revenu profit
factor line ad howev rais guidanc
midpoint fulli encompass sizeabl ep beat
impli less meaning ramp admittedli
consider investor scrutini rais ep
reflect ep upsid lower share count tax rate off-set
temper profit assumpt tp stand
revenu profit ahead revenu well
stronger core growth vs estimate medic
shi plan stronger volum partial off-set
exceed plan note specialti strength medic
profit growth disappoint reflect increas cost
privat label product aforement divestitur
ebitda margin fell bp bp plan gener million
cash facilit million dividend
share may retreat despit upsid cah share may subsid
lower impli pharma experi larg maintain segment
profit guidanc continu transit year
on-going profit pressur across pharma medic segment
expos prolong challeng diversif strategi focu
call like remain medic profit ramp pharmaceut growth
driver opioid litig portfolio optim risk drug price
acquisit miscu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
healthcar servic product compani
distribut brand gener pharmaceut well broad
varieti medic surgic product
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
compani mention price
